These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 22638798)

  • 21. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
    Lee JS; Yost SE; Blanchard S; Schmolze D; Yin HH; Pillai R; Robinson K; Tang A; Martinez N; Portnow J; Wen W; Yim JH; Brauer HA; Ren Y; Luu T; Mortimer J; Yuan Y
    Breast Cancer Res; 2019 Nov; 21(1):119. PubMed ID: 31703728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
    Tabernero J; Rojo F; Calvo E; Burris H; Judson I; Hazell K; Martinelli E; Ramon y Cajal S; Jones S; Vidal L; Shand N; Macarulla T; Ramos FJ; Dimitrijevic S; Zoellner U; Tang P; Stumm M; Lane HA; Lebwohl D; Baselga J
    J Clin Oncol; 2008 Apr; 26(10):1603-10. PubMed ID: 18332469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.
    Moroney J; Fu S; Moulder S; Falchook G; Helgason T; Levenback C; Hong D; Naing A; Wheler J; Kurzrock R
    Clin Cancer Res; 2012 Oct; 18(20):5796-805. PubMed ID: 22927482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
    Piha-Paul SA; Wheler JJ; Fu S; Levenback C; Lu K; Falchook GS; Naing A; Hong DS; Tsimberidou AM; Kurzrock R
    Oncotarget; 2014 Apr; 5(7):1846-55. PubMed ID: 24742900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model.
    Vansteenkiste J; Solomon B; Boyer M; Wolf J; Miller N; Di Scala L; Pylvaenaeinen I; Petrovic K; Dimitrijevic S; Anrys B; Laack E
    J Thorac Oncol; 2011 Dec; 6(12):2120-9. PubMed ID: 21900840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer.
    Singh J; Novik Y; Stein S; Volm M; Meyers M; Smith J; Omene C; Speyer J; Schneider R; Jhaveri K; Formenti S; Kyriakou V; Joseph B; Goldberg JD; Li X; Adams S; Tiersten A
    Breast Cancer Res; 2014 Mar; 16(2):R32. PubMed ID: 24684785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
    Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Mekhail T; Bukowski RM; Budd GT; Triozzi P; Borden E; Ivy P; Chen HX; Dolwati A; Dreicer R
    Clin Cancer Res; 2009 Oct; 15(19):6277-83. PubMed ID: 19773375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Infante JR; Spigel DR; Peyton JD; Thompson DS; Lane CM; Clark BL; Rubin MS; Trent DF; Burris HA
    Cancer; 2010 Sep; 116(17):4122-9. PubMed ID: 20564157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
    Rosen PJ; Sweeney CJ; Park DJ; Beaupre DM; Deng H; Leitch IM; Shubhakar P; Zhu M; Oliner KS; Anderson A; Yee LK
    Clin Cancer Res; 2010 May; 16(9):2677-87. PubMed ID: 20406832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
    Giusti RM; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2009 Mar; 14(3):284-90. PubMed ID: 19282350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers.
    Nemunaitis J; Hochster HS; Lustgarten S; Rhodes R; Ebbinghaus S; Turner CD; Dodion PF; Mita MM
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):336-42. PubMed ID: 23615181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
    Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
    J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
    Andre F; Campone M; O'Regan R; Manlius C; Massacesi C; Sahmoud T; Mukhopadhyay P; Soria JC; Naughton M; Hurvitz SA
    J Clin Oncol; 2010 Dec; 28(34):5110-5. PubMed ID: 20975068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
    Rodrigues HV; Ke D; Lim J; Stephen B; Bellido J; Janku F; Zinner R; Tsimberidou A; Hong D; Piha-Paul S; Fu S; Naing A; Subbiah V; Karp D; Falchook G; Kurzrock R; Wheler J
    Invest New Drugs; 2015 Jun; 33(3):700-9. PubMed ID: 25902899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC; Barbeau S; McMillian A; Srinivas S
    Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
    Hollebecque A; Houédé N; Cohen EE; Massard C; Italiano A; Westwood P; Bumgardner W; Miller J; Brail LH; Benhadji KA; Soria JC
    Eur J Cancer; 2014 Mar; 50(5):876-84. PubMed ID: 24456794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
    Langenberg MHG; Witteveen PO; Roodhart J; Lolkema MP; Verheul HMW; Mergui-Roelvink M; Brendel E; Krätzschmar J; Loembé B; Nol-Boekel A; Christensen O; Schellens JHM; Voest EE
    Ann Oncol; 2011 Nov; 22(11):2508-2515. PubMed ID: 21378200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.
    Nwankwo N; Zhang Z; Wang T; Collins C; Resta L; Ermisch S; Day J; Decker R; Kornberg L; Nicol S; Thornton D; Armstrong DK; Carducci MA
    Invest New Drugs; 2013 Jun; 31(3):653-60. PubMed ID: 22766773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.